Want to see NCNA full AI Analyst Report?
NCNA Stock Chart & Stats
$2.03
-$0.06(-4.88%)
At close: 4:00 PM EST
$2.03
-$0.06(-4.88%)
Day’s Range― - ―
52-Week Range$1.33 - $25.53
Previous CloseN/A
Volume88.96K
Average Volume (3M)174.33K
Market Cap
$5.66M
Enterprise Value-$12.36M
Total Cash (Recent Filing)$21.53M
Total Debt (Recent Filing)$680.03K
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.05
Shares Outstanding4,161,971
10 Day Avg. Volume84,221
30 Day Avg. Volume174,327
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market Cap-2.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.55
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low debt (TTM debt-to-equity ~0.03) materially reduces leverage-related bankruptcy and refinancing risk, preserving financial flexibility to fund R&D. This structural conservatism supports runway extension and strategic optionality while clinical programs advance.
Proprietary ProTide Platform & PipelineNuCana’s ProTide technology and multiple lead candidates (NUC-3373, NUC-7738) provide a durable competitive position versus generic chemotherapies if clinical efficacy is proven. A platform-based R&D model can spawn follow-on assets and partnerships, reducing single-product binary risk.
Cash Runway Into 2029Management reports cash runway into 2029, which materially lowers near-term financing pressure and allows the company to deliver planned clinical data and to refine registrational strategy for NUC-7738 without immediate dilutive capital raises.
Bears Say
No Product RevenueAs a clinical-stage biotech with no commercial products, NuCana lacks recurring revenue and reports sustained net losses (TTM ~30.8M). Continued operating deficits will progressively erode equity and force dependence on external financing absent successful clinical readouts.
Negative Cash Flow And Burn VolatilityPersistent negative operating and free cash flow (TTM OCF ~-7.2M, FCF ~-4.2M) and volatile FCF trends (sharp decline ~42.6%) indicate ongoing cash burn and unpredictable funding needs. This structural weakness increases probability of future equity raises before commercialization.
Eroding Equity / Balance-sheet DepletionMaterial decline in shareholders' equity (from ~65.5M in 2021 to ~22.4M TTM) reduces the company’s buffer to absorb future losses or trial setbacks. This structural erosion limits strategic flexibility and raises the stakes on upcoming clinical milestones.
Nucana News
NCNA FAQ
What was Nucana Plc’s price range in the past 12 months?
Nucana Plc lowest stock price was $1.33 and its highest was $25.53 in the past 12 months.
What is Nucana Plc’s market cap?
Nucana Plc’s market cap is $5.66M.
When is Nucana Plc’s upcoming earnings report date?
Nucana Plc’s upcoming earnings report date is Aug 13, 2026 which is in 40 days.
How were Nucana Plc’s earnings last quarter?
Nucana Plc released its earnings results on May 14, 2026. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is Nucana Plc overvalued?
According to Wall Street analysts Nucana Plc’s price is currently Overvalued.
Does Nucana Plc pay dividends?
Nucana Plc does not currently pay dividends.
What is Nucana Plc’s EPS estimate?
Nucana Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nucana Plc have?
Nucana Plc has 4,161,971 shares outstanding.
What happened to Nucana Plc’s price movement after its last earnings report?
Nucana Plc reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went up 10.101%.
Which hedge fund is a major shareholder of Nucana Plc?
Currently, no hedge funds are holding shares in NCNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nucana Plc
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.36% Other Institutional Investors
99.64% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---